

# Updated Review Fees for Industry-Sponsored Protocols

Human Gene Transfer & Innovative Uses of Radiation

• Effective July 1, 2026

Beginning July 1, 2026, the Office of Research Protections (ORP) will implement updated fees for industry-sponsored human participant protocol reviews involving **Human Gene Transfer** and **Innovative Uses of Radiation** (e.g., radiopharmaceuticals). These fees are in addition to [IRB charges](#) for the review of industry-sponsored protocols.

## ⚠ SCOPE OF APPLICABILITY

These fees apply only to industry-sponsored studies involving human participants. They do not apply to animal or bench research, nor to studies funded by sources other than industry.

These fees reflect the increased complexity and regulatory oversight required for these types of studies. They will support enhanced review processes and compliance resources.

## FEES EFFECTIVE JULY 1, 2026

### IBC

Institutional Biosafety Committee Review

**\$2,500**

Per industry-sponsored human participant protocol

### RSC

Radiation Safety Committee Review

**\$2,000**

Per industry-sponsored human participant protocol

## ① FEE SHEET UPDATE

The [fee sheet](#) used to collect IRB review fees will be revised on July 1, 2026 to allow IRB fees and ancillary review fees to be collected together in a single submission.

## FEE WAIVER ELIGIBILITY

### ◆ FEE WAIVER ELIGIBILITY

A waiver of the IBC and Radiation Safety review fees may be granted when the industry collaborator is not funding the entire study, but is supporting the study solely by providing the investigational drug or other nominal support. To request a waiver, email [vcorp@pitt.edu](mailto:vcorp@pitt.edu).

